USCOM LIMITED — Capital/Financing Update 2014

Oct 26, 2014

==> picture [57 x 49] intentionally omitted <==

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

USCOM Sale into Space Programme

SYDNEY, Australia, 27th October 2014: Uscom Limited (ASX code: UCM) announced the sale of an USCOM unit to the Russian Federal Space Agency.

The USCOM 1A has been commissioned for high level research of cardiovascular physiology in astronauts before, during and after space travel. The influence of weightlessness on the circulation is not well understood in part because there has previously not been available an accurate, noninvasive method to monitor the circulation. It is anticipated that the use of the USCOM device will provide an improved understanding of the circulation of astronauts in space.

Executive Chairman of Uscom, Dr Rob Phillips said “ This is another area of circulatory research which can be advanced by the USCOM technology. The high accuracy and sensitivity of the USCOM device results in many unique applications in which USCOM can improve our understanding of physiology and contribute to the global body of cardiovascular knowledge. The results of the USCOM in space physiology research may be translated into improved clinical care in heart failure, hypertension, sepsis and the guidance of fluid therapy.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way cardiovascular diseases, including hypertension, heart failure and sepsis are diagnosed and treated, and improving guidance of fluid, inotropes and vasoactive therapies.

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Both devices are clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures cardiovascular function, detects irregularities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic oscillometric Central Blood Pressure monitor and replaces older and more widespread sub systolic blood pressure monitoring technology. Central blood pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips Executive Chairman rob@uscom.com.au Ph: +61 2 9247 4144

Catherine Officer Company Secretary secretary@uscom.com.au